{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:30:23Z","timestamp":1762507823075,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early phase clinical trials have demonstrated good therapeutic index for oncolytic adenoviruses in patients with solid tumours when administered intratumorally, resulting in local tumour elimination. Entrapment and binding of adenovirus to erythrocytes, blood factors, and neutralising antibodies have prevented efficient systemic delivery and targeting of distant lesions in the clinic. We previously generated the novel replication-selective Ad-3\u2206-A20T to improve tumour targeting by increasing the viral dose at distant sites. Here, we developed a protocol to directly radiolabel the virus for rapid and sensitive detection by single-photon emitted computed tomography (SPECT\/CT) providing a convenient method for determining biodistribution following intravenous administration in murine models. Longitudinal whole-body scans, demonstrated efficient viral uptake in pancreatic Suit-2 and Panc04.03 xenografts with trace amounts of <jats:sup>125<\/jats:sup>I-Ad-3\u2206-A20T up to 48\u2009h after tail vein delivery. Hepatic and splenic radioactivity decreased over time. Analysis of tissues harvested at the end of the study, confirmed potency and selectivity of mutant viruses. Ad-3\u2206-A20T-treated animals showed higher viral genome copy numbers and E1A gene expression in tumors than in liver and spleen compared to Ad5wt. Our direct radiolabeling approach, allows for immediate screening of novel oncolytic adenoviruses and selection of optimal viral genome alterations to generate improved mutants.<\/jats:p>","DOI":"10.1038\/s41598-019-49150-9","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:22:00Z","timestamp":1567776120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systemic delivery and SPECT\/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Y. K.","family":"Stella Man","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabete","family":"Carapu\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Sosabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnel","family":"Halld\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"49150_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/mt.2015.125","volume":"23","author":"A Koski","year":"2015","unstructured":"Koski, A. et al. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. Molecular therapy: the journal of the American Society of Gene Therapy 23, 1641\u20131652 (2015).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"49150_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 107, 1373\u20131379 (2016).","journal-title":"Cancer Sci"},{"key":"49150_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","volume":"434","author":"CB Nattress","year":"2018","unstructured":"Nattress, C. B. & Hallden, G. Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett 434, 56\u201369 (2018).","journal-title":"Cancer Lett"},{"key":"49150_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","volume":"113","author":"RC Carlisle","year":"2009","unstructured":"Carlisle, R. C. et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909\u20131918 (2009).","journal-title":"Blood"},{"key":"49150_CR5","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1128\/JVI.02562-08","volume":"83","author":"MI Jonsson","year":"2009","unstructured":"Jonsson, M. I. et al. Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J Virol 83, 3816\u20133825 (2009).","journal-title":"J Virol"},{"key":"49150_CR6","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","volume":"79","author":"DM Shayakhmetov","year":"2005","unstructured":"Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y. & Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79, 7478\u20137491 (2005).","journal-title":"J Virol"},{"key":"49150_CR7","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","volume":"116","author":"R Alba","year":"2010","unstructured":"Alba, R. et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116, 2656\u20132664 (2010).","journal-title":"Blood"},{"key":"49150_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/biomedicines2010036","volume":"2","author":"R Alemany","year":"2014","unstructured":"Alemany, R. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines 2, 36\u201349 (2014).","journal-title":"Biomedicines"},{"key":"49150_CR9","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/oncotarget.2901","volume":"6","author":"O Hemminki","year":"2015","unstructured":"Hemminki, O. et al. Immunological data from cancer patients treated with Ad5\/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 6, 4467\u20134481. (2015).","journal-title":"Oncotarget"},{"key":"49150_CR10","doi-asserted-by":"crossref","unstructured":"Uusi-Kerttula, H. et al. Ad5NULL-A20: A Tropism-Modified, alphavbeta6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clin Cancer Res (2018).","DOI":"10.1158\/1078-0432.CCR-18-1089"},{"key":"49150_CR11","doi-asserted-by":"crossref","unstructured":"\u00d6berg, D et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (Ad\u2206\u2206) in prostate and pancreatic cancers. Clin Canc Res: 541\u2013553 (2010).","DOI":"10.1158\/1078-0432.CCR-09-1960"},{"key":"49150_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","volume":"17","author":"YKS Man","year":"2018","unstructured":"Man, Y. K. S. et al. The Novel Oncolytic Adenoviral Mutant Ad5-3Delta-A20T Retargeted to alphavbeta6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Mol Cancer Ther 17, 575\u2013587 (2018).","journal-title":"Mol Cancer Ther"},{"key":"49150_CR13","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3390\/v2102290","volume":"2","author":"L Coughlan","year":"2010","unstructured":"Coughlan, L. et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2, 2290\u20132355 (2010).","journal-title":"Viruses"},{"key":"49150_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1128\/JVI.01480-07","volume":"82","author":"D Dicara","year":"2008","unstructured":"Dicara, D. et al. Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness. J Virol 82, 1537\u20131546 (2008).","journal-title":"J Virol"},{"key":"49150_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000443180","volume":"97","author":"RJ Slack","year":"2016","unstructured":"Slack, R. J. et al. Pharmacological Characterization of the alphavbeta6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2. Pharmacology 97, 114\u2013125 (2016).","journal-title":"Pharmacology"},{"key":"49150_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1172\/JCI200523183","volume":"115","author":"RC Bates","year":"2005","unstructured":"Bates, R. C. et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. The Journal of clinical investigation 115, 339\u2013347 (2005).","journal-title":"The Journal of clinical investigation"},{"key":"49150_CR17","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-08-4410","volume":"69","author":"SH Hausner","year":"2009","unstructured":"Hausner, S. H. et al. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 69, 5843\u20135850 (2009).","journal-title":"Cancer Res"},{"key":"49150_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1078-0432.CCR-13-1504","volume":"20","author":"MD Allen","year":"2014","unstructured":"Allen, M. D. et al. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res 20, 344\u2013357 (2014).","journal-title":"Clin Cancer Res"},{"key":"49150_CR19","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1128\/JVI.00445-09","volume":"83","author":"L Coughlan","year":"2009","unstructured":"Coughlan, L. et al. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 83, 6416\u20136428 (2009).","journal-title":"J Virol"},{"key":"49150_CR20","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1089\/hum.2011.218","volume":"23","author":"L Coughlan","year":"2012","unstructured":"Coughlan, L. et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther 23, 960\u2013979 (2012).","journal-title":"Hum Gene Ther"},{"key":"49150_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/S12094-009-0330-1","volume":"11","author":"MT Macias","year":"2009","unstructured":"Macias, M. T. Use of radionuclides in cancer research and treatment. Clin Transl Oncol 11, 143\u2013153 (2009).","journal-title":"Clin Transl Oncol"},{"key":"49150_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1099\/0022-1317-35-1-181","volume":"35","author":"EH Frost","year":"1977","unstructured":"Frost, E. H. Radioactive labelling of viruses: an iodination technique preserving biological properties. J Gen Virol 35, 181\u2013185 (1977).","journal-title":"J Gen Virol"},{"key":"49150_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2018.06.008","volume":"66","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. [(18)F]Diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain. Nucl Med Biol 66, 1\u20139 (2018).","journal-title":"Nucl Med Biol"},{"issue":"Suppl 1","key":"49150_CR24","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1007\/s00259-011-2014-7","volume":"39","author":"P Laverman","year":"2012","unstructured":"Laverman, P., Sosabowski, J. K., Boerman, O. C. & Oyen, W. J. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 39(Suppl 1), S78\u201392 (2012).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"49150_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3109\/10837459809009865","volume":"3","author":"MA Croyle","year":"1998","unstructured":"Croyle, M. A., Roessler, B. J., Davidson, B. L., Hilfinger, J. M. & Amidon, G. L. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharmaceutical development and technology 3, 373\u2013383 (1998).","journal-title":"Pharmaceutical development and technology"},{"key":"49150_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jps.20496","volume":"95","author":"J Rexroad","year":"2006","unstructured":"Rexroad, J., Evans, R. K. & Middaugh, C. R. Effect of pH and ionic strength on the physical stability of adenovirus type 5. Journal of pharmaceutical sciences 95, 237\u2013247 (2006).","journal-title":"Journal of pharmaceutical sciences"},{"key":"49150_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/hum.2005.16.281","volume":"16","author":"M Lusky","year":"2005","unstructured":"Lusky, M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 16, 281\u2013291 (2005).","journal-title":"Hum Gene Ther"},{"key":"49150_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01317899","volume":"59","author":"F Galdiero","year":"1979","unstructured":"Galdiero, F. Adenovirus aggregation and preservation in extracellular environment. Arch Virol 59, 99\u2013105 (1979).","journal-title":"Arch Virol"},{"key":"49150_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0029-1210932","volume":"95","author":"KP Woltanski","year":"1990","unstructured":"Woltanski, K. P., Besch, W., Keilacker, H., Ziegler, M. & Kohnert, K. D. Radioiodination of peptide hormones and immunoglobulin preparations: comparison of the chloramine T and iodogen method. Exp Clin Endocrinol 95, 39\u201346 (1990).","journal-title":"Exp Clin Endocrinol"},{"key":"49150_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0006-291X(78)91322-0","volume":"80","author":"PJ Fraker","year":"1978","unstructured":"Fraker, P. J. & Speck, J. C. Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80, 849\u2013857 (1978).","journal-title":"Biochem Biophys Res Commun"},{"key":"49150_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/cgt.2011.45","volume":"18","author":"M Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, M., Francis, J., Eddouadi, A., Lemoine, N. R. & Hallden, G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer gene therapy 18, 734\u2013743 (2011).","journal-title":"Cancer gene therapy"},{"key":"49150_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jconrel.2012.05.025","volume":"164","author":"AC Bradshaw","year":"2012","unstructured":"Bradshaw, A. C. et al. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of controlled release: official journal of the Controlled Release Society 164, 394\u2013402 (2012).","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"49150_CR33","doi-asserted-by":"crossref","unstructured":"Nguyen, T. V. et al. Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5. Biomedicines 5 (2017).","DOI":"10.3390\/biomedicines5030046"},{"key":"49150_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.actbio.2015.11.005","volume":"30","author":"G Fan","year":"2016","unstructured":"Fan, G. et al. Bio-inspired polymer envelopes around adenoviral vectors to reduce immunogenicity and improve in vivo kinetics. Acta Biomater 30, 94\u2013105 (2016).","journal-title":"Acta Biomater"},{"key":"49150_CR35","doi-asserted-by":"crossref","unstructured":"Morales-Molina, A et al. (2018). Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. Cancer Immunol Immunother.","DOI":"10.1007\/s00262-018-2220-2"},{"key":"49150_CR36","doi-asserted-by":"publisher","first-page":"e1004673","DOI":"10.1371\/journal.ppat.1004673","volume":"11","author":"J Ma","year":"2015","unstructured":"Ma, J. et al. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog 11, e1004673 (2015).","journal-title":"PLoS Pathog"},{"key":"49150_CR37","first-page":"7431","volume":"14","author":"MH Yuan","year":"2017","unstructured":"Yuan, M. H. et al. Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na(131)I\/5-FC on human thyroid cancer. Oncol Lett 14, 7431\u20137436 (2017).","journal-title":"Oncol Lett"},{"key":"49150_CR38","doi-asserted-by":"publisher","first-page":"e32871","DOI":"10.1371\/journal.pone.0032871","volume":"7","author":"M Rajecki","year":"2012","unstructured":"Rajecki, M. et al. SPECT\/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I. PLoS One 7, e32871 (2012).","journal-title":"PLoS One"},{"key":"49150_CR39","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ctrv.2014.07.003","volume":"40","author":"H Oettle","year":"2014","unstructured":"Oettle, H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev 40, 1039\u20131047 (2014).","journal-title":"Cancer Treat Rev"},{"key":"49150_CR40","doi-asserted-by":"publisher","first-page":"e1001142","DOI":"10.1371\/journal.ppat.1001142","volume":"6","author":"AC Bradshaw","year":"2010","unstructured":"Bradshaw, A. C. et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 6, e1001142 (2010).","journal-title":"PLoS Pathog"},{"key":"49150_CR41","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-08-2008","volume":"15","author":"S Leitner","year":"2009","unstructured":"Leitner, S. et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 15, 1730\u20131740 (2009).","journal-title":"Clin Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49150-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49150-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49150-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:16:22Z","timestamp":1671282982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49150-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["49150"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-49150-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12840"}}